not tagged
dizal pharmaceuticals
['nsclc', 'sclc', 'dizal']
an #esmo22 scoop from : after posting head-turning ph. 2 data, dizal is planning a ph. 3 trial in the u.s. of its nsclc treatment before the end of the year. the med targets a subset of patients with exon20 insertion mutations. 
Tweets by the Fierce Life Sciences editorial team. Subscribe to our daily email newsletter at https://t.co/7Q6gUQgCIU